Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2019
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 23 Jun 2015 Efficacy at 24 months, results presented at the 1st Congress of the European Academy of Neurology.
- 30 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 03 Jun 2014 Interim results at 12 months presented at the 2014 Congress of European Neurology